CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF Determinants of exercise intolerance in heart failure with preserved ejection fraction: A systematic review and meta-analysis Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial Good response to tolvaptan shortens hospitalization in patients with congestive heart failure sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol

Original Research2018 Jun 5;71(22):2497-2506.

JOURNAL:J Am Coll Cardiol. Article Link

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Cavender MA, Norhammar A, CVD-REAL Investigators and Study Group. Keywords: CVD-REAL; cardiovascular disease; heart failure; sodium-glucose co-transporter-2 inhibitors

FULL TEXT PDF